Alemtuzumab, Fludarabine, Melphalan, and Thiotepa Conditioning for Transplantation in Inborn Errors of Immunity

20250 citationsJournal Articlehybrid Open Access

Authors

Thomas Pfeiffer · Washington University in St. Louis

Lisa Murray · Washington University in St. Louis

Feng Gao · Washington University in St. Louis

Shalini Shenoy · Washington University in St. Louis

Melissa Mavers · Washington University in St. Louis

Robert J. Hayashi · Washington University in St. Louis

Troy C. Quigg

Abstract

This RIC allo-HCT regimen for treatment of IEI had excellent OS with resolution of underlying immune abnormality, reconstitution of normal immune function, and low rates of GVHD. Future efforts will focus on optimizing engraftment in infants.

Topics & Keywords

Immunodeficiency and Autoimmune Disorders Hematopoietic Stem Cell Transplantation Neonatal Health and Biochemistry

Publication Details

Published in: Transplantation and Cellular Therapy

DOI: 10.1016/j.jtct.2025.11.028

Field-Weighted Citation Impact: 0.00

Command Palette

Alemtuzumab, Fludarabine, Melphalan, and Thiotepa Conditioning for Transplantation in Inborn Errors of Immunity

Authors

Abstract

Topics & Keywords

Publication Details